The BCR-ABL IS (International Scale) Transcript Fusion Quantification test is a sensitive molecular assay performed on peripheral blood using real-time reverse transcription-polymerase chain reaction (RT-PCR).
Designed primarily for patients with chronic myeloid leukemia (CML), this test measures the quantity of specific fusion transcripts (such as p210). By standardizing the results onto the International Scale (IS), it allows clinicians to precisely track disease burden, evaluate therapeutic responses to tyrosine kinase inhibitors, and reliably monitor minimal residual disease (MRD) over time across different laboratories with high accuracy and reproducibility.

The BCR-ABL qualitative test performed on EDTA whole blood is a specialized molecular assay designed to detect the presence of the BCR-ABL fusion gene transcript, commonly known as the Philadelphia chromosome. This genetic abnormality is a hallmark of chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). By utilizing reverse transcription-polymerase chain reaction (RT-PCR) technology, the test identifies whether the specific gene rearrangement is present or absent in the patient's blood sample. It serves as a crucial initial diagnostic tool to confirm clinical suspicion, guide targeted therapies, and support personalized treatment planning for hematological malignancies.

The Bence Jones Protein qualitative test is a laboratory analysis used to detect free monoclonal immunoglobulin light chains (kappa or lambda) in urine. These abnormal proteins are frequently produced in excess by plasma cell disorders, most notably multiple myeloma, as well as Waldenström macroglobulinemia and amyloidosis. Detecting Bence Jones proteins aids clinicians in diagnosing and monitoring these conditions. While a qualitative test provides a straightforward positive or negative result to indicate their presence, it serves as a critical initial screening marker that often prompts further quantitative evaluation and comprehensive clinical workups for underlying monoclonal gammopathies.

The beryllium test—most commonly performed as the Beryllium Lymphocyte Proliferation Test (BeLPT)—is a specialized immunological assay used to evaluate sensitization to the toxic metal beryllium. Exposure primarily occurs in industries such as aerospace, electronics, and metal machining. The assay measures how a patient's white blood cells react when exposed to beryllium salts in a laboratory setting. A positive proliferation response indicates cellular sensitization, which serves as a crucial diagnostic marker for chronic beryllium disease (CBD). Early detection enables clinicians to monitor lung health, manage occupational exposure risks, and implement timely interventions before irreversible pulmonary fibrosis develops.

The Beta-2 Glycoprotein 1 IgG test is an automated immunoassay used to detect IgG-class autoantibodies directed against beta-2 glycoprotein 1, a key plasma protein. Elevated levels of these autoantibodies are strongly associated with antiphospholipid syndrome (APS), a systemic autoimmune condition characterized by recurrent arterial or venous thrombosis and adverse pregnancy outcomes. Along with lupus anticoagulant and anticardiolipin antibodies, this test serves as a major diagnostic criterion for APS. Identifying these antibodies helps clinicians stratify thrombotic risk, evaluate unexplained blood clotting events, and guide long-term management and therapeutic anticoagulation strategies for affected patients.

The Beta-2 Glycoprotein 1 IgM test is an immunoassay that detects IgM-class autoantibodies targeting beta-2 glycoprotein 1, a plasma protein involved in coagulation regulation. Elevated levels of these antibodies are strongly associated with Antiphospholipid Syndrome (APS), an autoimmune disorder predisposing individuals to recurrent blood clots (thrombosis) in arteries and veins, as well as pregnancy complications. While IgG is the primary isotype linked to APS, measuring IgM provides crucial supplementary diagnostic information, particularly in patients who are IgG-negative but exhibit strong clinical symptoms of APS. It aids in risk stratification and comprehensive diagnostic evaluation.